<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365921</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-HE-010</org_study_id>
    <nct_id>NCT03365921</nct_id>
  </id_info>
  <brief_title>A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)</brief_title>
  <official_title>An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Innovax Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia
      Coli) Hecolin®.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The adjuvant of vaccine might change, this study will be conducted with new adjuvant.
  </why_stopped>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate and GMC of anti-HEV IgG at Month 7.</measure>
    <time_frame>7 months</time_frame>
    <description>Measure anti-HEV IgG in serum samples at 7 month to evaluate the immunogenicity of the Hepatitis E vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions/events of all subjects</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Measure solicited local adverse reactions within 7 days after each vaccination; Measure solicited systematic adverse reactions within 7 days after each vaccination; Measure unsolicited adverse reactions within 30 days after vaccination; Measure serious adverse events occurred throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis E</condition>
  <arm_group>
    <arm_group_label>Hepatitis E vaccine lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis E vaccine lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis E vaccine lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</intervention_name>
    <description>Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.</description>
    <arm_group_label>Hepatitis E vaccine lot 1</arm_group_label>
    <arm_group_label>Hepatitis E vaccine lot 2</arm_group_label>
    <arm_group_label>Hepatitis E vaccine lot 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Aged over 18 years old to 50 years old on the day of enrollment 2. Axillary
             temperature is below than 37.0 ℃. 3.Negative serological markers for hepatitis E 4.
             Judged as healthy and eligible for vaccination by the investigators through a
             selfreported medical history and some physical examinations.

             5. Able to understand this study information and willing to comply with all study
             requirements.

             6. Willing to participate in this study and sign informed consent form.

        Exclusion Criteria:

          1. Pregnancy,breast-feeding or plan to be pregnant in 7 months;

          2. Administration of Hepatitis E Vaccine before the study;

          3. Participate in any other clinical trial during the study period;

          4. Use of any investigational product or non-registered product (drug or vaccine)within
             30 days preceding the first dose of the study vaccine or plan to use during the study
             period;

          5. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy
             for more than 14 days in the 6 months before entry, except local treatment;

          6. Administration of any immunoglobulin or blood products within 3 months preceding the
             first dose of the study vaccine,or plan to use during the study period;

          7. Administration of any inactivated vaccines within 14 days preceding the first dose of
             the study or attenuated live vaccines within 21 days preceding the first dose of the
             study;

          8. Had a fever (axillary temperature over 38°C) within 3 days or acute illness, or use
             systemic antibiotics or antiviral treatment within 5 days before vaccination;

          9. Immunodeficiency (such as HIV carriers), primary disease of important organs,
             malignant tumor, or any immune disease (such as systemic lupus erythematosus,
             arthritis pauperum, splenectomy or functional asplenia or other disease which might
             affect immune response), liver and kidney disease and other chronic disease history;

         10. History of allergic disease or history of serious adverse events occurring after
             vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain.
             Allergic history to any component of this vaccine.

        12. Asthma that needed emergency treatment, hospitalization, oral or intravenous
        corticosteroid to keep stable in the past two years; 12. Combining another severe internal
        medicine disease(such as cardiopathy,diabetes and hyperthyroidism) 13. Anormal coagulation
        function or coagulopathy diagnosed by doctor; 14. Epilepsy(not including alcohol epilepsy
        within 3 years prior to abstinence and simple epilepsy that do without curing within 3
        years prior to the study ) 15. Anomal psychology or mind affecting the individual's ability
        to obey the study requirement; 16. Other medical, psychological, social or occupational
        factors that, according to the investigators' judgment,might affect the individual's
        ability to obey the protocol or sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuemei Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Prevention and Control</affiliation>
  </overall_official>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis E</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

